ABL Bio doubles down on self-sustainable growth beyond licensing deals
By
The Korea Herald
1d ago
Source
The Korea HeraldABL Bio doubles down on self-sustainable growth beyond licensing dealskoreaherald.comABL Bio is seeking to transform itself from a licensing-focused biotech company into a globally competitive drug developer while advancing both its oncology pipeline and proprietary platform technologies. “The dream is no longer signing another large licensing agreement,” Lee Sang-hoon, CEO of ABL Bio, said at a press conference at the Conrad Seoul on Thursday. "The goal is building a company that can stand shoulder to shoulder with global pharmaceutical companies." The vision comes as ABL Bio e
You might also wanna read
China creates new regulatory pathway to accelerate access to advanced biomedical therapies
China has established a new regulatory "tech track" for advanced therapies like personalized cancer treatments, cell and gene therapies, and
biopharmadive.com·23d ago
China's biotech rise: A case study in multiple myeloma drug development
This article examines China's rapid advancement in biotechnology through the lens of a multiple myeloma drug development case study. It disc
writingruxandrabio.com·15d ago
How AI Will Transform Biopharma: The Sequence of Change Matters
Ben Liu, CEO of Formation Bio, argues that AI will transform the pharmaceutical industry unevenly and sequentially. Some parts of drug disco
a16z.news·17d agoGreater Bay Area emerges as launchpad for China's biotech rise
shanghaisun.com·4d ago
Nanoleaf pivots from smart lighting to wellness, robotics, and AI
Nanoleaf is pivoting from smart lighting to focus on wellness, robotics, and AI, according to CEO Gimmy Chu. The company has been quiet for
The Verge·2mo ago
Basel Area Business & Innovation partners with Korean biopharma firms Roche Korea, KHIDI, and KIBO
Basel Area Business & Innovation has announced a new collaboration with Korean biopharma companies including Roche Korea, the Korea Health I
biospectrumasia.com·1mo ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.